Description

📄 Product Description:

Venclyxto® 100 mg by AbbVie contains Venetoclax, a selective BCL-2 inhibitor used in the treatment of Chronic Lymphocytic Leukemia (CLL) and Acute Myeloid Leukemia (AML). It induces apoptosis in cancer cells by inhibiting BCL-2, a protein that helps cancer cells survive.

Venclyxto is a targeted oral therapy designed for precision treatment, especially in relapsed/refractory hematologic malignancies. It is often used in combination with agents like Rituximab, Azacitidine, or Decitabine.

⚠️ Indications:

• Chronic Lymphocytic Leukemia (CLL)

• Small Lymphocytic Lymphoma (SLL)

• Acute Myeloid Leukemia (AML) (ineligible for intensive chemo)

🧪 Dosage & Administration (Overview):

• Typically initiated at low doses and gradually titrated (e.g., 20mg → 50mg → 100mg…)

• Always co-administered with a ramp-up schedule to minimize Tumor Lysis Syndrome (TLS) risk

• Should be used under supervision of a specialist oncologist

🧠 Mode of Action:

Venetoclax selectively inhibits B-cell lymphoma-2 (BCL-2), restoring the apoptotic process in malignant cells and triggering programmed cancer cell death.

📦 Packaging Details:

• Brand Name: Venclyxto

• Generic Name: Venetoclax

• Strength: 100 mg

• Form: Film-coated tablet

• Pack Size: 112 tablets (4 x 28 blister packs)

• Manufacturer: AbbVie

• Administration: Oral

• Prescription: Required

• Shelf Life: 24-36 months

• Storage: Store below 30°C

🌍 Export & B2B Supply Information:

✅ WHO-GMP compliant
✅ Available for export & tender supply
✅ Bulk rates for hospitals, NGOs, cancer centers
✅ Fast logistics to Africa, Asia, LATAM, CIS, GCC regions
✅ Multilingual labeling available